Profile data is unavailable for this security.
About the company
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
- Revenue in CNY (TTM)2.27bn
- Net income in CNY46.95m
- Incorporated1997
- Employees1.85k
- LocationZhejiang Starry Pharmaceutical Co LtdXianjuTAIZHOU 317300ChinaCHN
- Phone+86 57 687718605
- Fax+86 57 687718686
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lionco Pharmaceutical Group Co Ltd | 200.39m | -144.55m | 3.60bn | 475.00 | -- | 3.92 | -- | 17.96 | -0.2071 | -0.2071 | 0.2826 | 1.27 | 0.1182 | 1.86 | 2.52 | 421,872.40 | -8.52 | 0.7396 | -9.94 | 0.9562 | 42.74 | 80.88 | -72.13 | 2.08 | 6.19 | -5.98 | 0.3512 | 521.93 | -31.95 | -34.79 | 22.65 | -- | -33.18 | -- |
| Qingdao Vland Biotech INC | 1.25bn | 82.87m | 3.65bn | 1.57k | 43.36 | 2.12 | -- | 2.91 | 0.3326 | 0.3326 | 5.02 | 6.81 | 0.4431 | 3.42 | 4.33 | 797,663.40 | 3.80 | 5.78 | 5.77 | 7.89 | 45.38 | 46.13 | 8.58 | 10.34 | 0.8387 | 149.27 | 0.2896 | 33.59 | 3.07 | 8.05 | 15.56 | -0.6507 | 24.68 | -6.89 |
| Obio Technology Shanghai Corp Ltd | 233.59m | -138.37m | 3.66bn | 731.00 | -- | 1.81 | -- | 15.66 | -0.2157 | -0.2157 | 0.3624 | 3.11 | 0.0921 | 3.37 | 2.52 | 319,545.50 | -5.45 | 0.2246 | -5.99 | 0.2514 | -9.53 | 36.72 | -59.21 | 1.48 | 2.39 | -- | 0.1103 | 0.00 | -29.69 | 35.88 | -425.90 | -- | 57.00 | -- |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.27bn | 46.95m | 3.82bn | 1.85k | 81.57 | 2.17 | -- | 1.68 | 0.1368 | 0.1368 | 6.63 | 5.15 | 0.4179 | 1.98 | 5.09 | 1,231,642.00 | 0.8789 | 3.30 | 1.80 | 5.97 | 23.86 | 32.35 | 2.10 | 8.21 | 0.4121 | 1.44 | 0.6405 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Chengdu Olymvax Biopharmaceuticals Inc | 500.05m | -12.30m | 3.94bn | 471.00 | -- | 4.39 | -- | 7.87 | -0.0303 | -0.0303 | 1.23 | 2.21 | 0.3338 | 0.4197 | 1.08 | 1,061,669.00 | -1.22 | 3.17 | -1.70 | 4.68 | 93.29 | 93.00 | -3.64 | 7.44 | 1.92 | -3.90 | 0.2505 | 9.82 | -9.38 | 45.40 | -33.94 | -- | 56.47 | -- |
| Tibet Weixinkang Medicine Co Ltd | 1.29bn | 248.69m | 3.94bn | 701.00 | 15.85 | 2.75 | -- | 3.06 | 0.5715 | 0.5715 | 2.96 | 3.30 | 0.7114 | 18.19 | 5.88 | 1,840,383.00 | 13.71 | 8.20 | 17.78 | 11.13 | 50.81 | 50.20 | 19.28 | 11.53 | 3.10 | -- | 0.0045 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 222.11m | 4.03bn | 1.16k | 18.15 | 2.26 | -- | 2.78 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
Data as of Jun 03 2024. Currency figures normalised to Zhejiang Starry Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 5.67m | 1.66% |
| Rongtong Fund Management Co., Ltd.as of 30 Sep 2022 | 5.25m | 1.53% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 4.61m | 1.35% |
| Galaxy Asset Management Co., Ltd.as of 31 Dec 2023 | 2.39m | 0.70% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 2.24m | 0.66% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.88m | 0.55% |
| China Resources SZITIC Trust Co., Ltd.as of 30 Sep 2022 | 1.76m | 0.51% |
| Tebon Fund Management Co. Ltd.as of 30 Jun 2023 | 1.36m | 0.40% |
| The Vanguard Group, Inc.as of 09 May 2024 | 924.68k | 0.27% |
| Essence Fund Co., Ltd.as of 31 Dec 2023 | 789.26k | 0.23% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
